Search

Your search keyword '"Holmgaard, Rikke B."' showing total 17 results
Start Over Author "Holmgaard, Rikke B."
17 results on '"Holmgaard, Rikke B."'

3. Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade

Author

Holmgaard, Rikke B., Schaer, David A., Li, Yanxia, Castaneda, Stephen P., Murphy, Mary Y., Xu, Xiaohong, Inigo, Ivan, Dobkin, Julie, Manro, Jason R., Iversen, Philip W., Surguladze, David, Hall, Gerald E., Novosiadly, Ruslan D., Benhadji, Karim A., Plowman, Gregory D., Kalos, Michael, and Driscoll, Kyla E.

Published
2018
Full Text
View/download PDF

4. The New Era of Cancer Immunotherapy

Author

Khalil, Danny N., primary, Budhu, Sadna, additional, Gasmi, Billel, additional, Zappasodi, Roberta, additional, Hirschhorn-Cymerman, Daniel, additional, Plitt, Tamar, additional, De Henau, Olivier, additional, Zamarin, Dmitriy, additional, Holmgaard, Rikke B., additional, Murphy, Judith T., additional, Wolchok, Jedd D., additional, and Merghoub, Taha, additional

Published
2015
Full Text
View/download PDF

7. Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor

Author

Yingling, Jonathan M., primary, McMillen, William T., additional, Yan, Lei, additional, Huang, Huocong, additional, Sawyer, J. Scott, additional, Graff, Jeremy, additional, Clawson, David K., additional, Britt, Karen S., additional, Anderson, Bryan D., additional, Beight, Douglas W., additional, Desaiah, Durisala, additional, Lahn, Michael M., additional, Benhadji, Karim A., additional, Lallena, Maria J., additional, Holmgaard, Rikke B., additional, Xu, Xiaohong, additional, Zhang, Faming, additional, Manro, Jason R., additional, Iversen, Philip W., additional, Iyer, Chandrasekar V., additional, Brekken, Rolf A., additional, Kalos, Michael D., additional, and Driscoll, Kyla E., additional

Published
2017
Full Text
View/download PDF

10. The PTEN pathway in T regs is a critical driver of the suppressive tumor microenvironment

Author

Sharma, Madhav D., primary, Shinde, Rahul, additional, McGaha, Tracy L., additional, Huang, Lei, additional, Holmgaard, Rikke B., additional, Wolchok, Jedd D., additional, Mautino, Mario R., additional, Celis, Esteban, additional, Sharpe, Arlene H., additional, Francisco, Loise M., additional, Powell, Jonathan D., additional, Yagita, Hideo, additional, Mellor, Andrew L., additional, Blazar, Bruce R., additional, and Munn, David H., additional

Published
2015
Full Text
View/download PDF

16. The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment

Author

Sharma, Madhav D., Shinde, Rahul, McGaha, Tracy L., Huang, Lei, Holmgaard, Rikke B., Wolchok, Jedd D., Mautino, Mario R., Celis, Esteban, Sharpe, Arlene H., Francisco, Loise M., Powell, Jonathan D., Yagita, Hideo, Mellor, Andrew L., Blazar, Bruce R., and Munn, David H.

Subjects
SciAdv r-articles, Cancer Immunotherapy, tumor immunology, tumor microenvironment, Regulatory T cells, Tregs, PTEN, indoleamine 2, 3-dioxygenase
Abstract

The tumor microenvironment is profoundly immunosuppressive. We show that multiple tumor types create intratumoral immune suppression driven by a specialized form of regulatory T cell (Treg) activation dependent on the PTEN (phosphatase and tensin homolog) lipid phosphatase. PTEN acted to stabilize Tregs in tumors, preventing them from reprogramming into inflammatory effector cells. In mice with a Treg-specific deletion of PTEN, tumors grew slowly, were inflamed, and could not create an immunosuppressive tumor microenvironment. In normal mice, exposure to apoptotic tumor cells rapidly elicited PTEN-expressing Tregs, and PTEN-deficient mice were unable to maintain tolerance to apoptotic cells. In wild-type mice with large established tumors, pharmacologic inhibition of PTEN after chemotherapy or immunotherapy profoundly reconfigured the tumor microenvironment, changing it from a suppressive to an inflammatory milieu, and tumors underwent rapid regression. Thus, the immunosuppressive milieu in tumors must be actively maintained, and tumors become susceptible to immune attack if the PTEN pathway in Tregs is disrupted.

Published
2015
Full Text
View/download PDF

17. The New Era of Cancer Immunotherapy: Manipulating T-Cell Activity to Overcome Malignancy.

Author

Khalil DN, Budhu S, Gasmi B, Zappasodi R, Hirschhorn-Cymerman D, Plitt T, De Henau O, Zamarin D, Holmgaard RB, Murphy JT, Wolchok JD, and Merghoub T

Subjects
Animals, B7-H1 Antigen antagonists & inhibitors, Humans, Signal Transduction drug effects, T-Lymphocytes drug effects, Antineoplastic Agents therapeutic use, Immunotherapy, Neoplasms immunology, Neoplasms therapy, T-Lymphocytes immunology
Abstract

Using the immune system to control cancer has been investigated for over a century. Yet it is only over the last several years that therapeutic agents acting directly on the immune system have demonstrated improved overall survival for cancer patients in phase III clinical trials. Furthermore, it appears that some patients treated with such agents have been cured of metastatic cancer. This has led to increased interest and acceleration in the rate of progress in cancer immunotherapy. Most of the current immunotherapeutic success in cancer treatment is based on the use of immune-modulating antibodies targeting critical checkpoints (CTLA-4 and PD-1/PD-L1). Several other immune-modulating molecules targeting inhibitory or stimulatory pathways are being developed. The combined use of these medicines is the subject of intense investigation and holds important promise. Combination regimens include those that incorporate targeted therapies that act on growth signaling pathways, as well as standard chemotherapy and radiation therapy. In fact, these standard therapies have intrinsic immune-modulating properties that can support antitumor immunity. In the years ahead, adoptive T-cell therapy will also be an important part of treatment for some cancer patients. Other areas which are regaining interest are the use of oncolytic viruses that immunize patients against their own tumors and the use of vaccines against tumor antigens. Immunotherapy has demonstrated unprecedented durability in controlling multiple types of cancer and we expect its use to continue expanding rapidly., (© 2015 Elsevier Inc. All rights reserved.)

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results